PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Roflumilast - Chronic Obstructive Pulmonary Disease (COPD)
PAD Profile : Roflumilast - Chronic Obstructive Pulmonary Disease (COPD)
Keywords :
Chronic Obstructive Pulmonary Disease
Brand Names Include :
Daxas
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Tablets
Important Information :
Restricted to initiation by respiratory specialists in line with NICE TA461.
https://www.gov.uk/drug-safety-update/roflumilast-daxas-risk-of-suicidal-behaviour
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
- Aerivio Spiromax (Fluticasone/Salmeterol) DPI
- Airflusal (Salmeterol/Fluticasone) MDI
- Trimbow NEXThaler (formoterol/beclometasone/glycop
- Sereflo Ciphaler (Salmeterol / Fluticasone) DPI
- Campona Airmaster (Salmeterol / Fluticasone) DPI
- Dupilumab
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
04 October 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends roflumilast as a treatment option for COPD in line with NICE TA461
Roflumilast will be considered BLUE on the traffic light system with initiation by respiratory consultants.
There should be a minimum of 3 months prescribing in secondary care prior to transfer of care to primary care prescribers.
Associated BNF Codes
03. Respiratory System
03.03.03. Phosphodiesterase Type-4 inhibitors